

PUBLICATIONS

- 1) Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, Althoff KN, Silverberg MJ, Brooks JT, Kitahata MM, Goedert JJ, Grover S, Mayor AM, Moore RD, Park LS, Rachlis A, Sigel K, Sterling TR, Thorne JE, Pfeiffer RM. **Cancer-attributable mortality among people with treated HIV infection in North America.** Accepted for publication in CID
- 2) Bohlius J; AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. **Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study.** Clin Infect Dis. 2017 May 20. [Epub ahead of print]
- 3) Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. **Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared to the General Population.** J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):568-576. PMCID: PMC5522001
- 4) Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Hall HI, Kaplan EH. **A Flow-Based Model of the HIV Care Continuum in the United States.** J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):548-553. PMCID: PMC5533168
- 5) Anderegg N, Johnson LF, Zaniewski E, Althoff KN, Balestre E, Law M, Nash D, Shepherd BE, Yiannoutsos CT, Egger M; IeDEA, MeSH consortia. **All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up.** AIDS. 2017 Apr;31 Suppl 1:S31-S40. PMCID: PMC5540664
- 6) Muzaale AD, Althoff KN, Sperati CJ, Abraham AG, Kucirka LM, Massie AB, Kitahata MM, Horberg MA, Justice AC, Fischer MJ, Silverberg MJ, Butt AA, Boswell SL, Rachlis AR, Mayor AM, Gill MJ, Eron JJ, Napravnik S, Drozd DR, Martin JN, Bosch RJ, Durand C, Locke JE, Moore RD, Lucas GM, Segev DL. **Risk of End Stage Renal Disease in HIV-positive Potential Live Kidney Donors.** Am J Transplant. 2017 Jul;17(7):1823-1832. PMCID: PMC5489376
- 7) Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessel NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ. **Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada.** J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):382-390. PMCID: PMC5490794
- 8) Rebeiro PF, Abraham AG, Horberg MA, Althoff KN, Yehia BR, Buchacz K, Lau BM, Sterling TR, Gange SJ. **Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada.** AIDS Patient Care STDS. 2017 Mar;31(3):129-144 Epub 2017 Feb 27. PMCID: PMC5359655
- 9) Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN. **First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013.** Clin Infect Dis. 2017 Feb 15;64(4):459-467.
- 10) Shiels MS, Althoff KN, Pfeiffer RM, Achenbach CJ, Abraham AG, Castilho J, Cescon A, D'Souza G, Dubrow R, Eron JJ, Gebo K, John Gill M, Goedert JJ, Grover S, Hessel NA, Justice A, Kitahata

- M, Mayor A, Moore RD, Napravnik S, Novak RM, Thorne JE, Silverberg MJ, Engels EA. **HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers**. Clin Infect Dis. 2017 Feb 15;64(4):468-475.
- 11) Fritz CQ, Blevins M, Lindegren ML, Wools-Kaloutsian K, Musick BS, Cornell M, Goodwin K, Addison D, Dusingize JC, Messou E, Poda A, Duda SN, McGowan CC, Law MG, Moore RD, Freeman A, Nash D, Wester CW. **Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014**. J Int AIDS Soc. 2017 Jan 6;20(1):1-14. PMID: PMC5463912
 - 12) Althoff KN. **The Shifting Paradigm of Care for Adults Living With HIV: Smoking Cessation for Longer Life**. J Infect Dis. 2016 Dec 1;214(11):1618-1620. PMID: PMC5144730
 - 13) Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT. **Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010**. J Infect Dis. 2016 Sep 15;214(6):862-72. PMID: PMC4996145
 - 14) Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R; North American AIDS Cohort Collaboration on Research and Design of IeDEA. **Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras**. Clin Infect Dis. 2016 Nov 1;63(9):1160-1167. PMID: PMC5064164
 - 15) Rachlis B, Karwa R, Chema C, Pastakia S, Olsson S, Wools-Kaloustian K, Jakait B, Maina M, Yotebieng M, Kumarasamy N, Freeman A, de Rekeneire N, Duda SN, Davies MA, Braitstein P. **Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale**. Drug Saf. 2016 Oct;39(10):959-76. PMID: PMC5018020
 - 16) Koethe JR, Jenkins CA, Lau B, Shepherd BE, Wester W, Rebeiro PF, Silverberg MJ, Thorne JE, Gill J, Mayor AM, Willig A, Bosch R, Horberg MA, Justice AC, Sterling TR, Moore RD. **Higher Time-updated Body Mass Index: Association with Improved CD4+ Cell Recovery on HIV Treatment**. J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):197-204. PMID: PMC5023455
 - 17) Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). **Timing of Antiretroviral Treatment, Immunovirologic Status and TB Risk: Implications for Test and Treat**. J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572-8. PMID: PMC4942351
 - 18) Althoff KN, Rebeiro PF, Hanna DB, Padgett D, Horberg MA, Grinsztejn B, Abraham AG, Hogg R, Gill MJ, Wolff MJ, Mayor A, Rachlis A, Williams C, Sterling TR, Kitahata MM, Buchacz K, Thorne JE, Cesar C, Cordero FM, Rourke SB, Sierra-Madero J, Pape JW, Cahn P, McGowan C; North American Aids Cohort Collaboration on Research and Design (NA-ACCORD) and Caribbean, Central and South America Network for Hiv Epidemiology (CCASAnet). **A Picture is Worth a Thousand Words: Maps of HIV Indicators to Inform Research, Programs, and Policy from NA-ACCORD and CCASAnet Clinical Cohorts**. J Int AIDS Soc. 2016 Apr 4;19(1):20707. PMID: PMC4821890
 - 19) Cesar C, Koethe JR, Giganti MJ, Rebeiro P, Althoff KN, Napravnik S, Mayor A, Grinsztejn B, Wolff M, Padgett D, Sierra-Madero J, Gotuzzo E, Sterling TR, Willig J, Levison J, Kitahata M, Rodriguez-

- Barradas MC, Moore RD, McGowan C, Shepherd BE, Cahn P; Caribbean, Central and South America Network for HIV epidemiology (CCASAnet) and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Health Outcomes Among HIV-Positive Latinos Initiating Antiretroviral Therapy in North America versus Central and South America.** *J Int AIDS Soc.* 2016 Mar 18;19(1):20684. PMID: PMC4800379
- 20) Rebeiro PF, Gange SJ, Horberg MA, Abraham AG, Napravnik S, Samji H, Yehia BR, Althoff KN, Moore RD, Kitahata MM, Sterling TR, Curriero FC; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Geographic Variations in Retention in Care among HIV-Infected Adults in the United States.** *PLoS One.* 2016 Jan 11;11(1):e0146119. PMID: PMC4708981
- 21) Rebeiro PF, Althoff KN, Lau B, Gill J, Abraham AG, Horberg MA, Kitahata MM, Yehia BR, Samji H, Brooks JT, Buchacz K, Napravnik S, Silverberg MJ, Rachlis A, Gebo KA, Sterling TR, Moore RD, Gange SJ; North American AIDS Cohort Collaboration on Research and Design. **Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America.** *Am J Epidemiol.* 2015 Dec 1;182(11):952-60. PMID: PMC4655744
- 22) Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, Wester CW, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada.** *AIDS Res Hum Retroviruses.* 2016 Jan;32(1):50-8. PMID: PMC4692122
- 23) Koethe JR, Jenkins CA, Lau B, Shepherd BE, Silverberg MJ, Brown TT, Blashill AJ, Anema A, Willig A, Stinnette S, Napravnik S, Gill MJ, Crane HM, Sterling TR. **Body Mass Index and Early CD4+ T-cell Recovery among Adults Initiating Antiretroviral Therapy in North America, 1998-2010.** *HIV Med.* 2015 Oct;16(9):572-7. PMID: PMC4558259
- 24) Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol N, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD and Dubrow R for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Cumulative Incidence of Cancer among HIV-infected Individuals in North America.** *Ann Intern Med.* 2015 Oct 6;163(7):507-18. PMID: PMC4711936
- 25) Poteat T, Hanna DB, Althoff KN. **Feasibility and acceptability of developing a multi-site clinical cohort of transgender people with HIV infection.** *AIDS Res Hum Retroviruses.* 2015 Sep;31(9):870-2. PMID: PMC4808270
- 26) Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, Lo Re V, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM and Moore RD. **Ascertainment and verification of end-stage renal and liver disease in the North American AIDS Cohort Collaboration on Research and Design.** *AIDS Res Treat.* 2015; 2015:923194. Epub 2015 Feb 19. PMC4350581
- 27) Geng EH, Neilands TB, Thièbaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN. **CD4+ T cell Recovery during**

- Suppression of HIV Replication: a Global Comparison of the Immunologic Efficacy of Antiretroviral Therapy.** *Int J Epidemiol.* 2015 Feb;44(1):251-63. PMC4339766
- 28) Yehia BR, Rebeiro PF, Althoff KN, Agwu AL, Horberg MA, Samji H, Napravnik S, Mayer KH, Tedaldi E, Silverberg MJ, Thorne JE, Burchell AN, Rourke SB, Rachlis A, Mayor A, Gill MJ, Zinski A, Ohl M, Anastos K, Abraham AG, Kitahata MM, Moore RD and Gebo KA; for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **The Impact of Age on Retention in Care and Viral Suppression.** *J Acquir Immune Defic Syndr.* 2015 Apr 1;68(4):413-9. PMC4334738
- 29) Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, Bosch RJ, Crane HM, Eron JJ, Gill MJ, Horberg MA, Justice AC, Klein MB, Mayor AM, Moore RD, Palella FJ, Parikh CR, Silverberg MJ, Golub ET, Jacobson LP, Napravnik S, Lucas GM; for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). **End Stage Renal Disease among HIV-Infected Adults in North America.** *Clin Infect Dis.* 2015 Mar 15;60(6):941-9. PMC4357817
- 30) Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, Ekouevi DK, Egger M, Hemingway-Foday J, Cooper DA, Moore RD, McGowan CC, Nash D; International Epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. **Characteristics and Comprehensiveness of Adult HIV Care and Treatment Programmes in Asia-Pacific, Sub-Saharan Africa and the Americas: Results of a Site Assessment Conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.** *J Int AIDS Soc.* 2014 Dec 15;17:19045. PMC4268491
- 31) Rebeiro PF, Horberg MA, Gange SJ, Gebo KA, Yehia BR, Brooks JT, Buchacz K, Silverberg MJ, Gill MJ, Moore RD, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Strong Agreement of Nationally Recommended Retention Measures from the Institute of Medicine and Department of Health and Human Services.** *PLoS One.* 2014 Nov 6;9(11):e111772. PMC4222946
- 32) Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Burchell AN, Korthuis PT, Moore RD, D'Souza G; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Incidence and Risk Factors of HPV-Related and HPV-Unrelated Head and Neck Squamous Cell Carcinoma in HIV-Infected Individuals.** *Oral Oncol.* 2014 Dec;50(12):1169-76. PMC4253676
- 33) Wong C, Althoff KN, Gange SJ. **Identifying the appropriate comparison group for HIV-infected individuals.** *Curr Opin HIV AIDS.* 2014 Jul;9(4):379-85. PMC4105851
- 34) Althoff KN, Rebeiro PF, Brooks JT, Buchacz K, Gebo KA, Martin JN, Hogg RS, Thorne JE, Klein MB, Gill MJ, Sterling TR, Yehia BR, Silverberg MJ, Crane HM, Justice AC, Gange SJ, Moore RD, Kitahata MM, Horberg MA for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Disparities in the Quality of HIV Care when Using US Department of Health and Human Services Indicators.** *Clin Infect Dis.* 2014 Apr;58(8):1185-9. PMC3967825
- 35) Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata MM, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonnyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R,

NA-ACCORD Publications, Presentations and Reports

- Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M. **Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries.** *J Acquir Immune Defic Syndr.* 2014 Jan 1;65(1):e8-16. PMC3894575
- 36) Samji H, Cescon A, Hogg RS, Modur S, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice AC, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore RD, Gange SJ for The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada.** *PLoS One.* 2013 Dec 18;8(12):e81355. PMC3867319
- 37) Hanna DB, Buchacz K, Gebo KA, Hessel NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Collier A, Samji H, Thorne JE, Althoff KN, Martin JN, Rodriguez B, Stuart EA, Gange SJ; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). **Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.** *PLoS One.* 2013 Nov 18;8(11):e78952. PMC3657490
- 38) Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, Fine DM, Klein MB, Silverberg MJ, Gill MJ, Moore RD, Gebo KA, Sterling TR, Butt AA; NA-ACCORD of the IeDEA. **Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.** *J Infect Dis.* 2013 Oct 15;208(8):1240-9. Epub 2013 Jul 31. PMC3778973
- 39) Hanna DB, Buchacz K, Gebo KA, Hessel NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, Gange SJ; for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS. **Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009.** *Clin Infect Dis.* 2013 Apr;56(8):1174-82. PMC3657490
- 40) Abraham AG, Strickler HD, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, Saag MS, Rourke SB, Rachlis A, Napravnik S, Moore RD, Klein MB, Kitahata MM, Kirk G, Hogg RS, Hessel NA, Goedert JJ, Gill MJ, Gebo KA, Eron JJ, Engels EA, Dubrow R, Crane HM, Brooks JT, Bosch RJ, D'Souza G; for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Invasive cervical cancer risk among HIV-infected women: A North American multi-cohort collaboration prospective study.** *J Acquir Immune Defic Syndr.* 2013 Apr 1;62(4):405-13. PMC3633634.
- 41) Rebeiro PF, Althoff KN, Buchacz K, Gill MJ, Horberg MA, Krentz H, Brooks JT, Gebo KA, Sterling TR, Moore RD, Mugavero MJ, Martin JN, Klein MB, Hogg RS, Silverberg MJ, Rourke SB, Thorne J and Gange SJ; for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Retention Among North American HIV-infected Persons in Clinical Care, 2000-2008.** *J Acquir Immune Defic Syndr.* 2013 Mar 1;62(3):356-62. PMC3661708.
- 42) Justice AC, Modur S, Tate J, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron JJ, Willig JH, Moore RD, Kirk GD, Bosch RJ, Rodriguez B, Hogg RS, Thorne JE, Goedert JJ, Klein MB, Gill MJ, Deeks SG, Sterling TR, Anastos K, Gange SJ; for the NA-ACCORD and VACS Project Teams. **Predictive Accuracy of the Veterans Aging Cohort Study (VACS) Index for Mortality with HIV Infection: A North**

- American Cross Cohort Analysis.** *J Acquir Immune Defic Syndr.* 2013 Feb 1;62(2):149-63. PMC3619393
- 43) Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro PF, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT; North American AIDS Cohort Collaboration on Research and Design. **U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.** *Ann Intern Med.* 2012 Sep 4;157(5):325-35. PMC3534765
- 44) Silverberg MJ, Lau B, Justice AC, Engels EA, Gill MJ, Goedert JJ, Kirk GD, D'Souza G, Bosch RJ, Brooks JT, Napravnik S, Hessel NA, Jacobson LP, Kitahata MM, Klein MB, Moore RD, Rodriguez B, Rourke SB, Saag MS, Sterling TR, Gebo KA, Press N, Martin JN, Dubrow R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Risk of Anal Cancer in HIV-Infected and HIV-uninfected Individuals in North America.** *Clin Infect Dis* 2012 54(7):1026-34. PMC3297645
- 45) Sterling TR, Lau B, Zhang J, Freeman AM, Bosch RJ, Brooks JT, Deeks SG, French A, Gange SJ, Gebo KA, Gill MJ, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening.** *J Infect Dis.* 2011 204: 893-901. PMC3156918
- 46) Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron JJ, Harrigan R, Gill MJ, Kitahata MM, Klein MB, Napravnik S, Rachlis A, Rodriguez B, Rourke SB, Benson C, Bosch RJ, Collier A, Gebo KA, Goedert JJ, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Martin JN, McKaig RG, Silverberg MJ, Sterling TR, Thorne JE, Willig JH, Gange SJ. **Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America.** *Am J Epidemiol.* 2011 Sep 15;174(6):727-35. PMC21813792
- 47) Lau B, Cole SR, Gange SJ. **Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.** *Stat Med.* 2011 Mar 15;30(6):654-65. PMC21337360
- 48) Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC; for the North American AIDS Cohort Collaboration on Research and Design. **CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?** *AIDS Res Ther.* 2010 Dec 15;7(1):45. PMC3022663
- 49) Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA; for the North American AIDS Cohorts Collaboration on Research, Design (NA-ACCORD). **Virologic and immunologic response to HAART, by age and regimen class.** *AIDS.* 2010 Oct 23;24(16):2469-79. PMC20829678
- 50) Kitahata MM. **When to start antiretroviral therapy.** *Top HIV Med.* 2010 Aug-Sep;18(3):121-6. PMC20921578

- 51) Lau B, Chander G, Gange SJ, Moore RD. **Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study.** *AIDS Res Ther.* 2010 Jul 23;7:25. PMC2922076
- 52) Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. **Late Presentation for HIV Care in the United States and Canada.** *Clin Infect Dis.* 2010 Jun 1;50(11):1512-20. PMC2862849
- 53) Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD for the North American AIDS Cohort Collaboration on Research and Design. **Trends in Multi-Drug Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced HIV-Infected Patients in North America.** *Clin Infect Dis.* 2009 Nov; 49 (10): 1582–1590. PMC2871149
- 54) Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD, for the NA-ACCORD. **Effect of early versus delayed antiretroviral therapy for HIV on survival.** *N Engl J Med.* 2009;360:1815-1826. [With Editorial Commentary]. PMC2854555
- 55) Lau B, Gange SJ, Kirk GD, and Moore RD. **Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies.** *Epidemiology* 2009 20(5):664-72. PMC2818534
- 56) Lau B, Cole SR, and Gange SJ. **Competing risk regression models for epidemiologic data.** *Am J Epidemiol* 2009 Jul 15;170(2):244-56. PMC2732996
- 57) Lau B, Cole SR, Moore RD, Gange SJ. **Evaluating competing adverse and beneficial outcomes using a mixture model.** *Statistics in Medicine* 2008;27(21):4313-27. PMC2251745
- 58) Lau B, Gange SJ, Moore RD. **Interval and clinical cohort studies: epidemiological issues.** *AIDS Res Hum Retroviruses.* 2007 Jun;23(6):769-76. PMC 17604539
- 59) Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. **Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).** *Int J Epidemiol.* 2007 Apr;36(2):294-301. PMC2820873

PRESENTATIONS & REPORTS

2017

2017 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle

- 1) Althoff KN, Palella F, Gebo K, Gange SJ, Silverberg MJ, Rabkin C, Thorne J, Horberg MA, Kitahata MM, and Moore RD. **Impact of smoking, hypertension and cholesterol on myocardial infarction in HIV+ adults.** (Oral)

NA-ACCORD Publications, Presentations and Reports

- 2) Althoff KN, Horberg MA, Eron, J, Gange SJ, Crane HM, Justice AC, Kitahata MM, Margolick JB, Eyawo O, Moore RD. **The large gap between statin eligibility and prescription among HIV+ in North America.** (Poster)
- 3) Desir F, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, Horberg MA, Silverberg MJ, Althoff KN. **Retention, ART use, and viral suppression among young adults newly linked to HIV care.** (Poster)
- 4) Silverberg MJ, Leyden W, Lin H, Qin L, Achenbach CD, D'Souza G, Engels E, Rabkin C, Althoff KN, Neugebauer R. **Earlier versus delayed ART initiation and risk of cancer.** (Poster)
- 5) Wong C, Gange SJ, Moore RD, Justice AC, Abraham A, Gebo K, Gill MJ, Martin J, Mayor A, Althoff KN. **Trend in Multimorbidity Among HIV+ Adults in Clinical Care in the US.** (Poster)

2017 International Workshop on HIV Observational Databases (IWHOD), Lisbon, Portugal

- 6) Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin C, Goedert JJ, Thorne J, Mayor A, Crane HM, Kitahata MM, Klein MB, Kirk GD. **Risk of hepatocellular carcinoma among persons living with HIV and viral hepatitis co-infection in the United States and Canada, 1996-2009.** (Oral)
- 7) Althoff KN, Wong C, Hogan B, Desir F, Zhang J, Modur S, You B, Liu B, Jing Y, Horberg M, Rebeiro PF, Justice AC, Kitahata MM, Gange SJ. **Using observation windows for improving ascertainment assumptions in clinical cohort studies: Illustration of ascertaining diabetes outcomes.** (Poster)

2016

2016 WHO Report

- 8) **Report prepared for the IeDEA-WHO Collaboration: global analysis of retention in care in initial HIV care and treatment program, on behalf of the International Epidemiologic Databases to Evaluate AIDS (IeDEA).** Included in the World Health Organization's Department of HIV/AIDS 2016 Progress Report- **Prevent HIV, test and treat all - WHO support for country impact.** WHO/HIV/2016.24

2016 Inter-CFAR Collaboration on HIV Research in Women Symposium, Birmingham

- 9) Desir FA, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, Horberg MA, Silverberg MJ, and Althoff KN. **Retention, ART use, and viral suppression among women linked to HIV care in the United States.** (Oral)

2016 International AIDS Conference, Durban, South Africa

- 10) Rachlis B, Karwa R, Chema C, Pastakia S, Olsson S, Wools-Kaloustian K, Jakait B, Mercy Maina M, Yotebieng M, Kumarasamy N, Freeman AM, de Rekeneire N, Duda SN, Davies MA, Braitstein P. **Targeted Spontaneous Reporting: Scoping opportunities to conduct routine pharmacovigilance for antiretroviral treatment on an international scale.** (Poster)

2016 International Workshop on HIV Observational Databases (IWHOD), Budapest, Hungary

- 11) Rohner E, **CD4 cell trajectories in HIV-positive adults developing Kaposi Sarcoma after starting cART: a multiregional comparison based on nested case control studies.** (Poster)
- 12) Olga Tymejczyk, Constantin Yiannoutsos, Kara Wools-Kaloustian, Amit Achhra, Keri Althoff, Brenda Crabtree-Ramirez, Kinh Van Nguyen, Elizabeth Zaniewski, and Denis Nash for the IeDEA

NA-ACCORD Publications, Presentations and Reports

Collaboration. **Cumulative incidence of ART initiation at the original clinic of enrolment: An analysis of IeDEA network data from 241 clinics in 28 countries, 2004-2014.** (Poster)

- 13) Rebeiro PF, Mugavero MJ, Horberg MA, Mayer K, Martin JN, Kitahata MM, Abraham AG, Moore RD, Sterling TR, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Regional differences in ancillary care services for HIV-infected adults in the U.S.: potential policy implications.** (Poster)
- 14) George Rutherford, Aaron Kipp, Mary Lou Lindegren, Bryan E. Shepherd, C. William Wester, Kara Wools-Kaloustian, Constantin T. Yiannoutsos for the International epidemiological Databases to Evaluate AIDS (IeDEA) Consortium **Comparison of 48- and 96-week outcomes in adults initiating tenofovir + lamivudine/emtricitabine + efavirenz and those initiating two other nucleoside reverse transcriptase inhibitors + efavirenz using propensity-score matched IeDEA observational cohort data and data from randomised controlled trials.** (Oral)

2016 Conference on Retroviruses and Opportunistic Infections (CROI), Boston

- 15) Althoff KN, Eron JJ, Jacobson LP, Justice AC, Kirk GD, Klein MB, Lo Re V, Napravnik S, Silverberg MJ, Moore RD. **Hepatitis B and C, Alcohol, and CD4 drive End-Stage Liver Disease in HIV+ Adults** (Oral)
- 16) Althoff KN, Estrella M, Abraham AG, Gill MJ, Kitahata MM, Horberg MA, Hull M, Mayor A, Palella F, Lucas G. **The Racial Survival Paradox in HIV+ End-stage Renal Disease (ESRD) Patients** (Poster)
- 17) Wang R, Lucas G, Estrella M, Shlipak M, Harris M, Horberg MA, Kitahata MM, Mayor A, Napravnik S, Abraham AG. **Short-term Renal Impact of Tenofovir among HIV-infected patients in North America** (Poster)
- 18) Drozd D, Budoff M, Crane H, Eron JJ, Heckbert S, Justice AC, Kitahata MM, Klein D, Palella F, Moore RD. **Atherosclerotic Myocardial Infarction Risk in the NA-ACCORD Compared to MESA and ARIC** (Poster)
- 19) Grover S, Crane H, Gill MJ, Goedert JJ, K Kitahata MM, Moore RD, Napravnik S, Rachlis A, Silverberg MJ, Althoff KN. **No Difference in Stage at Cancer Diagnosis by AIDS Status Among HIV-infected Adults** (Poster)
- 20) Rohner E, Bütikofer L, Maskew M, Chen YA, Friedman R, D'Souza G, Egger M, Bohlius J. **Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy** (Themed Discussion)
- 21) Rohner E, Bohlius J, Bütikofer L, Maskew M, Chen YA, Fink V, Achenbach C, Egger M. **Risk of Kaposi Sarcoma in HIV-positive adults on ART: a global analysis** (Poster)

2016 American Society of Clinical Oncology (ASCO), Chicago

- 22) Rohner E, Bütikofer L, Maskew M, Fink V, Grinsztejn B, Achenbach C, Goedert J, Bohlius J. **NHL risk in HIV+ Adults on Antiretroviral Therapy in Four Continents** (Poster)

NA-ACCORD Publications, Presentations and Reports

2015

2015 International AIDS Society (IAS), Vancouver

- 23) Calkins K, Eron JJ, Abraham AG, Buchacz K, Horberg MA, Tate J, Napravnik S, Moore RD, Bosch RJ, Lau B. **CD4 reconstitution is related to CD4 at effective antiretroviral treatment initiation** (Poster)

2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle

- 24) Palella FJ, Althoff KN, Moore RD, Zhang J, Kitahata MM, Gange SJ, Crane HM, Drozd DR, Brooks JT, and Elion R. **Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD** (Poster)
- 25) Drozd DR, Kitahata MM, Althoff KN, Zhang J, Heckbert SR, Budoff MJ, Palella FJ, Klein DB, Moore RD, Crane HM. **Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD** (Themed Discussion)
- 26) leDEA and COHERE collaboration. **Immunodeficiency at the Start of ART: A Global View** (Themed Discussion)
- 27) Althoff KN, Gange SJ, Achenbach C, Jacobson LP, Mayor AM, Silverberg MJ, Justice AC, Moore RD, Yuezhou J, and Gebo KA. **Smoking Outweighs HIV-related Risk Factors for Non-AIDS-defining Cancers** (Poster)
- 28) Klein MB, Althoff KN, Jing Y, Kirk GD, Lo Re V, Kim N, Kitahata MM, Thio C, Silverberg MJ, Moore RD. **Has Modern ART reduced Endstage Liver Disease risk in HIV-Hepatitis coinfectd adults?** (Poster)
- 29) Ingle SM, Miro JM, Furrer H, Justice AC, Saag MS, Manzardo C, Esteve A, Cain LE, Sterne JAC, May MT on behalf of COHERE in EuroCoord, CNICS and NA-ACCORD. **Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings** (Themed Discussion)
- 30) Rebeiro PF, Yehia BR, Gebo KA, Lau B, Mayer KH, Horberg MA, Kitahata MM, Gill MJ. **Continuous Retention Predicts Viral Suppression Across the US and Canada** (Poster)
- 31) Wong C, Gange SJ, Horberg MA, Kirk GD, Rachlis A, Gill MJ, Thorne JE, Hogg RS, Goedert JJ, and Althoff KN. **Age-Related Morbidities Among HIV-Infected Adults From 2000-2010** (Poster)
- 32) Cesar CT, Giganti MJ, Shepherd BE, Moore RD, Althoff KN, Napravnik S, Mayor AM, McGowan C, Cahn PE. **Outcomes of first ART in Latino populations in North America and Latin America** (Poster)

2015 International Workshop on HIV Observational Databases (IWHOD), Catania, Sicily

- 33) Althoff KN, Jing Y, Gebo KA, Klein MB, Kitahata MM, Gill MJ, Dubrow R, Silverberg MJ, Samji H, Wong C, Rachlis A, Horberg MA, Lau B, Moore RD, Gange SJ, and Lucas GM. **Aging better with HIV: Using the population attributable fraction to inform interventions to reduce end-stage renal disease in HIV-infected adults** (Poster)
- 34) Wester CW, Jenkins CA, Koethe JR, Freeman AM, Kalayjian R, Mendes A, Abraham AG, Lake JE, Erlandson K, Crane HM, Sterling TR, Moore RD, and Shepherd BE. **Association between angiotensin receptor blocker and angiotensin converting enzyme inhibitor exposure and all-cause mortality in HIV-infected adults** (Poster)
- 35) Pettit AC, Mendes A, Jenkins CA, Napravnik S, Freeman AM, Shepherd BE, Dowdy D, Rachlis A, Moore RD, and Sterling TR. **Highly Active Antiretroviral Therapy Initiation and Incident TB in the US and Canada** (Oral)

NA-ACCORD Publications, Presentations and Reports

- 36) Rebeiro PF, Abraham AG, Horberg MA, Gill MJ, Yehia BR, Silverberg MJ, Rachlis AB, Samji H, Althoff KN, Sterling TR, and Gange SJ. **Racial differences in discontinuity and re-entry into HIV care after antiretroviral therapy initiation in the U.S. and Canada** (Poster)

2015 National Transgender Health Summit, Oakland, CA

- 37) Poteat T, Hanna D. **The feasibility and acceptability of developing a multi-site clinical cohort of transgender people with HIV infection** (Oral)

2015 Society for Research on Nicotine and Tobacco (SRNT), Philadelphia,

- 38) Johnson AL, Kirk GD, Drummond MB, O'Cleirigh CM, Hogg RS, Brooks JT, Moore RD, Horberg MA, Rourke SB, Mayor A, Gill MJ, Martin JN, Napravnik S, Eron JJ, Kitahata MM and Althoff KN. **Cigarette smoking and the relationship with retention in HIV care, 2008-2010** (Poster)

2015 Pepper Center Annual Meeting, Arlington

- 39) Althoff KN, Wong C, Gange SJ, Horberg MA, Kirk GD, Rachlis A, Gill MJ, Thorne JE, Hogg RS, and Justice AC. **Racial disparities persist into older ages in HIV-infected adults: The increased rate of hypertension, diabetes, and chronic kidney disease in Black vs. non-Black adults aging with HIV** (Poster)

2014

2014 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain

- 40) Rebeiro PF, Althoff KN, Lau B, Horberg MA, Mugavero MJ, Samji H, Napravnik S, Silverberg MJ, Rachlis A, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Labs are Imperfect Proxies of Encounters: Retention Trends in the Largest North American HIV Cohort.** (Poster)
- 41) Rebeiro PF, Gange SJ, Horberg MA, Abraham AG, Napravnik S, Samji H, Yehia BR, Althoff KN, and Curriero FC for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **The geography of HIV clinical retention in the United States: regional trends in the NA-ACCORD.** (Poster)
- 42) Koethe JR, Jenkins CA, Lau B, Sterling TR, and Shepherd BE for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Obesity Prevalence and Weight Gain among Adults Starting Antiretroviral Therapy in the United States and Canada, 1998 to 2010.** (Poster)
- 43) Ingle SM, Miro JM, Furrer H, Justice A, Saag M, Manzardo C, Esteve A, Sterne J, May M on behalf of COHERE, CNICS and NA-ACCORD. **Starting cART in antiretroviral-naïve HIV-1-infected patients presenting with cryptococcal meningitis.** (Poster)

2014 Conference on Retroviruses and Opportunistic Infections (CROI), Boston

- 44) Buchacz K, Lau B, Jing Y, Gange SJ, Moore RD and Brooks JT for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Incidence of AIDS-defining opportunistic illnesses (ADOIs) among patients with no prior clinical AIDS: the NA-ACCORD, 2000-2010.** (Poster)
- 45) Koethe JR, Jenkins CA, Lau B, Shepherd BE, Silverberg MJ, Blashill AJ, Anema A, Willig A, Stinnette S, Sterling TR, and North American AIDS Cohort Collaboration on Research and Design

NA-ACCORD Publications, Presentations and Reports

(NA-ACCORD) of the IeDEA. **Body Mass Index and CD4+ T-cell Recovery at 12 Months among Adults Initiating ART in the United States and Canada.** (Poster)

- 46) Pettit AC, Mendes A, Jenkins CA, Napravnik S, Freeman AM, Shepherd BE, Dowdy DR, Rachlis A, Moore RD and Sterling TR, for the NA-ACCORD investigators and IeDEA. **Antiretroviral Therapy Initiation and Tuberculosis (TB) Risk in the United States (US) and Canada.** (Poster)
- 47) Yehia BR, Rebeiro PF, Althoff KN, Gange SJ, Samji H, Horberg MA, Napravnik S and Gebo KA for the NA-ACCORD and IeDEA. **Age Impacts the Association of Retention in Care and Viral Suppression.** (Poster)

2013

2013 IAS, Malaysia

- 48) Hogg RS, Althoff KN, Samji H, Cescon A, Modur S, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice AC, Kirk GD, Klein MB, Korthuis PT, Martin JN, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks SG, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore RD, Gange SJ, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Increases in life expectancy among treated HIV-positive individuals in the United States and Canada, 2000-2007.** (Poster)
- 49) Althoff KN, Abraham AG, Estrella M, Crane HM, Freeman AM, Gill MJ, Golub ET, Horberg MA, Jacobson LP, Kitahata MM, McKaig R, Palella F, Parikh CR, Moore RD, Jing Y, Rodriguez B, Eron JJ, Napravnik S, Silverberg MJ, Mayor A, Krishnasami Z, Lucas GM for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Incidence of end stage renal disease in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).** (Poster)

2013 International Workshop on HIV Observational Databases (IWHOD), Croatia

- 50) Althoff KN, Rebeiro PF, Hanna DB, Hogg RS, Brooks JT, Abraham AG, Horberg MA, Buchacz K, Gill MJ, Mayor A, Burchell A, Rachlis A, Thorne JE, Sterling TR and Williams C, for the North American AIDS Cohort Collaboration on Research and Design. **Measures on the Map: A geographical display of HIV infection and care indicators.** (Oral)
- 51) Abraham AG, Modur S, Gange SJ, Eron JJ, Boswell S, Gill MJ, Justice AC, Martin JN, Mayor A, Moore RD and Deeks SG, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). **HIV Drug Resistance in Antiretroviral Therapy-Experienced Patients in North America: Current Trends in the Burden of Resistance.** (Poster)
- 52) Buchacz K, Lau B, Jing Y, Bosch RJ, Gandhi N, Gill MJ, Abraham AG, Napravnik S, Goedert JJ, Eron JJ, Martin JN, Patel P, Rourke SB, Samji H, Mayor A, Saag MS, Silverberg MJ, Gange SJ, Moore RD and Brooks JT for the NA-ACCORD. **Incidence of AIDS-defining opportunistic illnesses (ADOIs) among patients with no prior clinical AIDS: the NA-ACCORD, 2000-2010.** (Poster)
- 53) Janet Tate, Justice AC. **Does change in VACS Index predict mortality better than viral suppression and CD4 after one year of ART?** (Oral)

NA-ACCORD Publications, Presentations and Reports

2013 Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta

- 54) Althoff KN, Rebeiro PF, Horberg MA, Buchacz K, Gebo KA, Sterling TR, Kitahata MM, Justice AC, Moore RD for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Application of the Indicators for Monitoring Department of Health and Human Services-Funded HIV Services in the largest collaboration of HIV cohorts in North America.** (Oral & Poster)
- 55) Rebeiro PF, Horberg MA, Gebo KA, Brooks JT, Buchacz, Silverberg MJ, Gill MJ, Moore RD, Althoff KN for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **No meaningful difference between retention indicators from US government agencies within the largest HIV Cohort Collaboration in North America.** (Poster)
- 56) Lucas GM, Yuezhou Jing, Sulkowski M, Abraham AG, Atta M, Fine D, Moore RD and Estrella M for the North American AIDS Cohort Collaboration on Research and Design (NA ACCORD) of IeDEA. **Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter?** (Poster)

2012

2012 XIX International AIDS Conference

- 57) Silverberg MJ, Lau B, Jing Y, Achenbach C, Althoff KN, Bosch RJ, Brooks JT, Burchell A, Crane HM, D'Souza G, Gill MJ, Goedert JJ, Hessel NA, Justice AC, Hogg RS, Kirk GD, Kitahata MM, Klein MB, Martin JN, Mathews WC, Moore RD, Napravnik S, Novak R, Patel P, Rachlis A, Rodriguez B, Sterling TR, Willig JH, and Dubrow R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Risk of Common Cancers by Age 60 for HIV-infected Patients in the United States and Canada.** (Poster)
- 58) Shiels MS, Althoff KN, Achenbach C, Abraham AG, Burchell A, Cescon A, Crane HM, D'Souza G, Mathews WC, Gill MJ, Hessel NA, Justice AC, Kirk GD, Klein MB, Moore RD, Napravnik S, Novak R, Rodriguez B, Schouten J, Sterling TR, Thorne JE, Willig JH, Silverberg MJ and Engels EA for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Age at cancer diagnosis in HIV-infected individuals in North America compared to the general U.S. population.** (Poster)
- 59) Rebeiro PF, Althoff KN, Gill MJ, Horberg MA, Krentz H, Martin JN, Moore RD, Sterling TR, Gebo KA, Hogg RS, Justice AC, Kitahata MM, Klein MB, Mugavero MJ, Napravnik S, Rourke SB, Thorne JE, Gange SJ for North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Patterns and Predictors of Absences from HIV Care in North America (2000-2008).** (Poster presentation)
- 60) Hanna DB, Buchacz K, Hessel NA, Horberg MA, Jacobson LP, Kitahata MM, Moore RD, Napravnik S, Patel P, Gebo KA, Willig JH, Sterling TR, Kirk GD, Collier A, Ohl ME, Thorne JE, Rodriguez B, Martin JN, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Association Between State AIDS Drug Assistance Program (ADAP) Features and Treatment Initiation in Clinically Eligible U.S. HIV-infected Persons.** (Poster)
- 61) Althoff KN, Buchacz K, Hall I, Zhang J, Hanna DB, Rebeiro PF, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin JN, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Rodriguez B and Brooks JT for The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Trends in antiretroviral therapy use, HIV RNA plasma viral load, and CD4 T-lymphocyte counts at death among HIV-infected persons in care in the United States, 2000-2008.** (Oral &

Poster)

- 62) Abraham AG, Lau B, Estrella MM, Szczech L, Sterling TR, Rourke SB, Rodriguez B, Rachlis A, Parikh C, Napravnik S, Moore RD, Moore D, Martin JN, Klein MB, Kitahata MM, Kirk GD, Jing Y, Horberg MA, Harris M, Gill MJ, Gebo KA, Eron JJ, Crane HM, Bosch RJ, Benson C, Anastos K, Althoff KN, Lucas GM for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Tenofovir-Associated Kidney Function Decline with a PI-based Versus NNRTI-based Regimen.** (Poster)
- 63) Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthius PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Collier A, Ohl ME, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Trends in ART initiation and virologic suppression among newly clinically eligible HIV-infected individuals in North America, 2001 to 2009.** (Poster)
- 64) Geng EH, Neillands TB, Moore RD, Deeks SG, Easterbrook P, Wood R, Little F, Nachega J, Zannou DM, Yiannoutsos C, Thiebault R, Reynolds S, Vittinghoff E, Martin JN, International Epidemiologic Databases to Evaluate AIDS. **CD4+ T cell recovery during suppression of HIV replication on antiretroviral therapy: a global comparison of immunologic efficacy.** (Poster)

2012 Society for Epidemiologic Research

- 65) Hanna DB, Stuart EA and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Use of Propensity Score Matching to Assess the Effect of a State Policy on Treatment Outcomes in U.S. HIV-infected Persons.** (Poster)
- 66) Rebeiro PF, Althoff KN, Gill MJ, Krentz H, Gebo KA, Martin JN, Horberg MA, Hogg RS, Thorne JE, Klein MB, Sterling TR, Moore RD, Gange SJ for North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Modeling Clinical Retention in the North American HIV Population.** (Poster)

2012 Eurogin

- 67) D'Souza G, Strickler H, Jing Y, Sterling TR, Silverberg MJ, Samji H, Napravnik S, Moore RD, Mathews WC, Klein MB, Kitahata MM, Kirk GD, Gill MJ, Dubrow R, Burchell A, Brooks JT, Beachler DC and Abraham AG for North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Incidence and Risk Factors for Head and Neck Cancer and Cervical Cancer Among HIV-infected Individuals in North America.** (Poster)

2012 International Workshop on HIV Observational Databases (IWHOD), Athens

- 68) Rebeiro PF, Althoff KN, Gill MJ, Krentz H, Gebo KA, Horberg MA, Hogg RS, Thorne JE, Sterling TR, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Factors Associated with Absence from HIV Clinical Care Among Black Patients in the NA-ACCORD: Application of Beta-binomial and Transition Models to Observational Cohort Data.** (Poster)

2012 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle

- 69) Abraham AG, Jing Y, Beachler D, Silverberg MJ, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Moore RD, D'Souza G, for the North American AIDS Cohort Collaboration on Research and

NA-ACCORD Publications, Presentations and Reports

Design (NA-ACCORD) of IeDEA. **Incidence and Risk Factors for Oral Cancer Among HIV-Infected Individuals.** (Oral)

- 70) Hogg RS, Samji H, Cescon A, Modur SP, Napravnik S, Martin JN, Gill MJ, Klein MB, Kirk GD, Gange SJ, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Temporal changes in life expectancy of HIV-positive persons in North America.** (Oral)
- 71) Egger M, Mugglin C, Althoff KN, Wools-Kaloustian K, Sterne JAC, Nash D, Dabis F, Williams C, McGowan C and Cooper D for the IeDEA Collaboration and the ART Cohort Collaboration. **Immundeficiency at the Start of ART: Global View.** (Oral)
- 72) Hanna DB, Gebo KA, Hessel NA, Horberg MA, Kirk GD, Kitahata MM, Napravnik S, Sterling TR, Willig JH, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Disparities in Rates of HIV Treatment Initiation and Viral Load Suppression across U.S. States, 2001-2007.** (Poster)

2012 Report to the Institute of Medicine

- 73) **Report to the Institute of Medicine's Committee to Review Data Systems for Monitoring HIV Care.** Kitahata MM for the NA-ACCORD of the IeDEA. Published Report, March 15, 2012.

2011

2011 Conference on Retroviruses and Opportunistic Infections (CROI), Boston

- 74) Justice AC, Modur SP, Tate J, Althoff KN, Gange SJ, Jacobson LP, Gebo K, Kitahata MM, Horberg MA, Napravnik S for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Anti-Retroviral Therapy (cART).** (Poster)
- 75) Althoff KN, Rebeiro PF, Gill MJ, Michael Horberg, Eron JJ, Napravnik S, Anastos K, Bosch RJ, Moore RD, Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Trends in HIV Viral Load among adults in clinical care in the US and Canada, 1997-2007.** (Poster)

2011 International Workshop on HIV Observational Databases (IWHOD), Prague

- 76) Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS and Moore RD for the NA-ACCORD. **Characteristics of late presenters and timing of antiretroviral therapy initiation.** (Oral)
- 77) Abraham AG, Modur SP, Rosenblum M, Lau B, Zhang J, Eron JJ, Deeks SG, Moore RD, Crane HM, Gill MJ, Hogg RS, Kitahata MM, Klein MB, Rodriguez B, Rourke SB, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **Estimating the Time to HIV Drug Resistance in HIV-infected Individuals in North America.** (Poster)
- 78) Rebeiro PF, Althoff KN, Gill MJ, Brooks JT, Buchacz K, Gebo K, Martin JN, Horberg MA, Hogg RS, Thorne JE, Klein MB, Sterling TR, Moore RD, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **Sustained Care after Presentation among HIV-positive Adults in North America: the Importance of Churn in Observational Cohorts.** (Poster)

NA-ACCORD Publications, Presentations and Reports

2011 XVIII International AIDS Conference

- 79) Abraham AG, Gange SJ, Jing Y, Bosch RJ, Brooks JT, Dubrow R, Eron JJ, Gebo K, Gill MJ, Hessol NA, Hogg RS, Kitahata MM, Klein MB, Moore RD, Rourke SB, Silverberg MJ and D'Souza G for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. **CD4 count trajectories of HIV-infected women in North America with cervical cancer after initiating HAART.** (*Oral*)

2011 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies

- 80) D'Souza G, Jing Y, Strickler H, Silverberg MJ, Engels EA, Bosch RJ, Brooks JT, Dubrow R, Eron JJ, Gebo KA, Gill MJ, Hogg RS, Kitahata MM, Klein MB, Moore RD, Rourke SB, and Abraham AG for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Cervical cancer epidemiology in HIV-infected women in North America.** (*Oral*)
- 81) Silverberg MJ, Lau B, Jing Y, D'Souza G, Engels EA, Gill MJ, Goedert JJ, Kirk GD, Justice AC, and Dubrow R for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Risk of anal cancer in HIV-Infected patients and HIV-uninfected controls in North America.** (*Oral*)

2010

2010 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain

- 82) Gange SJ. **Methods for Evaluating When to Start Antiretroviral Therapy.** Invited plenary session speaker, 14th International Workshop on HIV Observational Databases, Sitges, Spain.
- 83) Hanna DB, Althoff KN, Lau B, Gebo KA, Justice AC, Kitahata MM, Moore RD and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design. **Inverse Probability Weighting Models for Evaluating the Impact of HAART: Examples from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).** (*Oral*)
- 84) Golub ET, Deeks SG, Hunt PW, Martin JN, Zhang J, Horberg MA, Gebo KA, Kitahata MM, Rachlis A, Greenblatt R, Saag MS, Kirk GD, Sterling TR, Napravnik S, Moore RD, and Gange SJ for the NA-ACCORD. **Prevalence of extreme virologic and immunologic control in North American HIV treatment sites.** (*Poster*)
- 85) Althoff KN, Justice AC, Gange SJ, Moore RD, Lau B, Deeks SG, and Gebo KA for the North American AIDS Cohort Collaboration on AIDS Research and Design. **Immunologic and virologic response to ART by decade of age and regimen class.** (*Poster*)

2010 Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco

- 86) Abraham AG, Gange SJ, Moore RD, Lau B, Harrigan R, and Deeks SG for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Methods for Estimating the Prevalence of Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America.** (*Poster*)
- 87) Geng E, Vittinghoff E, Nachege J, Moore RD, Wood R, Dabis F, Yiannoutsos C, Easterbrook P, Deeks SG, Martin JN, and International Epidemiologic Databases to Evaluate AIDS (IeDEA). **A comparison of the immunologic efficacy of antiretroviral therapy in resource-replete versus resource-limited settings.** (*Poster*)

NA-ACCORD Publications, Presentations and Reports

- 88) Althoff KN, Gange SJ, Klein MB, Horberg MA, Zhang J and Moore RD for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Late Presentation for HIV Care in the United States and Canada.** (*Poster*)
- 89) Silverberg MJ, Lau B, D'Souza G, Engels EA, Gill MJ, Goedert JJ, Kirk GD, Dubrow R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America.** (*Poster*)

2010 1st International Workshop on HIV & Aging

- 90) Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert MJ, McKaig RG, Thorne JE, Rachlis A, Moore RD, and Justice AC, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). **CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?** (*Oral*)

2010 Reports

- 91) **Report to the World Health Organization's Department of HIV/AIDS on effect of ART on tuberculosis in persons with a baseline CD4 > 350 in NA-ACCORD.** Lau B, Gange SJ, Zhang J, Saag MS and Moore RD for the NA-ACCORD of the IeDEA. Unpublished Report, October 22, 2010
- 92) **Report to the Institute of Medicine Committee Evaluating Disability Criteria for those with HIV Infection.** Justice AC, Gange SJ, Tate JP, Jacobson LP, Gebo K, Althoff KN, Kitahata MM, Saag MS, Horberg MA, Moore RD, for the NA-ACCORD and VACS Project Teams. Unpublished Report, June 9, 2010
- 93) DHHS Panel on Antiretroviral Treatment Guidelines Annual Meeting at CROI, Montreal: Kitahata MM, Gange SG, Moore RD. **Summary of 351-500 (ICAAC/IDSA 2008) and >500 (CROI 2009) presentations.** (*Oral presentation via special invitation from panel*)

2009

2009 Conference on Retroviruses and Opportunistic Infections (CROI), Montreal

- 94) Kitahata MM, Gange SG, Moore RD and North American AIDS Cohort Collaboration Research and Design (NA-ACCORD) of the IeDEA. **Initiating Rather than Deferring HAART at a CD4 count >500 cells/mm³ is Associated with Improved Survival.** (*Oral*)

2009 13th International Workshop on HIV Observational Databases (IWHOD), Lisbon

- 95) Abraham AG, Deeks SG and North American AIDS Cohort Collaboration Research and Design (NA-ACCORD) of the IeDEA. **Prevalence trends of Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005.** (*Poster*)
- 96) Althoff KN, Gange SJ, Gebo KA and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. Title: **Older age is inversely associated with immune recovery after HAART initiation in North America.** (*Poster*)

NA-ACCORD Publications, Presentations and Reports

2008

2008 Conference on Retroviruses and Opportunistic Infections (CROI), Boston

- 97) Deeks SG and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Trends in Second Virologic Failure and Predictors of Subsequent Mortality among Antiretroviral Therapy-Experienced Patients: North American Experience.** (Oral)
- 98) Sterling TR and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Tuberculosis after HAART Initiation in the United States and Canada.** (Poster)

2008 12th International Workshop on HIV Observational Databases (IWHOD), Spain

- 99) Gange SJ and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Trends and Predictors of Virologic Failure among Antiretroviral Therapy-Experienced Patients in North America: 1996-2005.** (Oral)

2008 IAS, Mexico

- 100) Deeks SG and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005.** (Poster)
- 101) Sterling TR and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Risk Factors for Tuberculosis Within 3 Months of HAART Initiation.** (Oral)

2008 XVII International Resistance Workshop, Spain

- 102) Deeks SG and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **The Prevalence of Multi-drug Resistance Among Treated Patients In North America and its Impact on Mortality.** (Poster)

2008 Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Washington

- 103) Kitahata MM and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. **Initiating Rather than Deferring HAART at a CD4 count Between 351-500 cells/mm³ is Associated with Improved Survival.** (Oral)

2008 NIAID/DAIDS Meeting, Bethesda

- 104) **Initiating Rather than Deferring HAART at a CD4+ Count Between 351-500 Cells/mm³ is Associated with Improved Survival.** (Special invitation to present a summary of the ICAAC/IDSA presentation)